Literature DB >> 16939499

Downregulation of hepcidin and haemojuvelin expression in the hepatocyte cell-line HepG2 induced by thalassaemic sera.

Orly Weizer-Stern1, Konstantin Adamsky, Ninette Amariglio, Carina Levin, Ariel Koren, William Breuer, Eliezer Rachmilewitz, Laura Breda, Stefano Rivella, Z Ioav Cabantchik, Gideon Rechavi.   

Abstract

Beta-thalassaemia represents a group of diseases, in which ineffective erythropoiesis is accompanied by iron overload. In a mouse model of beta-thalassaemia, we observed that the liver expressed relatively low levels of hepcidin, which is a key factor in the regulation of iron absorption by the gut and of iron recycling by the reticuloendothelial system. It was hypothesised that, despite the overt iron overload, a putative plasma factor found in beta-thalassaemia might suppress liver hepcidin expression. Sera from beta-thalassaemia and haemochromatosis (C282Y mutation) patients were compared with those of healthy individuals regarding their capacity to induce changes the expression of key genes of iron metabolism in human HepG2 hepatoma cells. Sera from beta-thalassaemia major patients induced a major decrease in hepcidin (HAMP) and lipocalin2 (oncogene 24p3) (LCN2) expression, as well as a moderate decrease in haemojuvelin (HFE2) expression, compared with sera from healthy individuals. A significant correlation was found between the degree of downregulation of HAMP and HFE2 induced by beta-thalassaemia major sera (r = 0.852, P < 0.0009). Decreased HAMP expression was also found in HepG2 cells treated with sera from beta-thalassaemia intermedia patients. In contrast, the majority of sera from hereditary haemochromatosis patients induced an increase in HAMP expression, which correlated with transferrin (Tf) saturation (r = 0.765, P < 0.0099). Our results suggest that, in beta-thalassaemia, serum factors might override the potential effect of iron overload on HAMP expression, thereby providing an explanation for the failure to arrest excessive intestinal iron absorption in these patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16939499     DOI: 10.1111/j.1365-2141.2006.06258.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  30 in total

Review 1.  Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia.

Authors:  Sara Gardenghi; Robert W Grady; Stefano Rivella
Journal:  Hematol Oncol Clin North Am       Date:  2010-10-15       Impact factor: 3.722

2.  Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia.

Authors:  Carla Casu; Mariam Aghajan; Paraskevi Rea Oikonomidou; Shuling Guo; Brett P Monia; Stefano Rivella
Journal:  Haematologica       Date:  2015-09-24       Impact factor: 9.941

3.  Hepcidin suppression in β-thalassemia is associated with the down-regulation of atonal homolog 8.

Authors:  Supranee Upanan; Andrew T McKie; Gladys O Latunde-Dada; Sittiruk Roytrakul; Chairat Uthaipibull; Peraphan Pothacharoen; Prachya Kongtawelert; Suthat Fucharoen; Somdet Srichairatanakool
Journal:  Int J Hematol       Date:  2017-04-12       Impact factor: 2.490

4.  Decreasing TfR1 expression reverses anemia and hepcidin suppression in β-thalassemic mice.

Authors:  Huihui Li; Tenzin Choesang; Weili Bao; Huiyong Chen; Maria Feola; Daniel Garcia-Santos; Jie Li; Shuming Sun; Antonia Follenzi; Petra Pham; Jing Liu; Jinghua Zhang; Prem Ponka; Xiuli An; Narla Mohandas; Robert E Fleming; Stefano Rivella; Guiyuan Li; Yelena Z Ginzburg
Journal:  Blood       Date:  2017-02-01       Impact factor: 22.113

5.  Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia.

Authors:  Ilaria V Libani; Ella C Guy; Luca Melchiori; Raffaella Schiro; Pedro Ramos; Laura Breda; Thomas Scholzen; Amy Chadburn; YiFang Liu; Margrit Kernbach; Bettina Baron-Lühr; Matteo Porotto; Maria de Sousa; Eliezer A Rachmilewitz; John D Hood; M Domenica Cappellini; Patricia J Giardina; Robert W Grady; Johannes Gerdes; Stefano Rivella
Journal:  Blood       Date:  2008-05-14       Impact factor: 22.113

6.  Variability of Iron Load in Patients of Sickle Cell Anaemia (HbSS): A study from Eastern India.

Authors:  Pranati Mohanty; Rabindra Kumar Jena; Sudha Sethy
Journal:  J Clin Diagn Res       Date:  2017-03-01

Review 7.  Regulation of iron absorption in hemoglobinopathies.

Authors:  Gideon Rechavi; Stefano Rivella
Journal:  Curr Mol Med       Date:  2008-11       Impact factor: 2.222

8.  Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin.

Authors:  Damien R Ashby; Daniel P Gale; Mark Busbridge; Kevin G Murphy; Neill D Duncan; Tom D Cairns; David H Taube; Stephen R Bloom; Frederick W K Tam; Richard Chapman; Patrick H Maxwell; Peter Choi
Journal:  Haematologica       Date:  2009-10-14       Impact factor: 9.941

9.  Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia.

Authors:  Saumya S Jamuar; Angeline H M Lai
Journal:  Ther Adv Hematol       Date:  2012-10

10.  Iron Loading and Overloading due to Ineffective Erythropoiesis.

Authors:  Toshihiko Tanno; Jeffery L Miller
Journal:  Adv Hematol       Date:  2010-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.